Rekvina Laboratories will launch an open offer to buy back 26% of its shares at ₹10 each, totaling ₹2.89 crore. This follows its acquisition of Radiant Parenterals, aiming to consolidate control despite widening losses and negative net worth.
Rekvina Laboratories Announces Open Offer Amid Acquisition
Rekvina Laboratories plans an open offer size of 28,90,100 shares, representing 26% of its expanded share capital, at an offer price of ₹10 per share. The maximum consideration for this offer amounts to ₹2.89 crore (₹289.01 lakh). The offer period is scheduled from July 1, 2026, to July 14, 2026.
Reader Takeaway: Open offer provides exit; weak financials pose a challenge.
What just happened
Rekvina Laboratories is executing an open offer to buy back shares at ₹10 per share. This is linked to the company's acquisition of Radiant Parenterals Limited through a Securities Exchange and Purchase Agreement (SEPA). The acquisition will be funded by a preferential issue of Rekvina shares to Radiant's sellers. Post-acquisition, Radiant will be a wholly-owned subsidiary, and Dhruvalkumar Patel will become a promoter.
Why this matters
This open offer gives public shareholders an exit route at a fixed price of ₹10 per share. However, the company faces significant financial challenges, including persistent losses and an eroding net worth, making it crucial for investors to assess the potential for a turnaround under the new ownership structure.
The backstory
Rekvina Laboratories has reported a net loss of ₹0.25 crore (₹25.47 lakh) for FY 2026, an increase from ₹0.14 crore (₹13.71 lakh) in FY 2025. The company's net worth has deteriorated further, standing at a negative ₹1.23 crore (₹122.82 lakh) as of March 31, 2026. These results highlight ongoing financial struggles.
What changes now
The acquisition of Radiant Parenterals is expected to consolidate control under new promoters. Following the transaction, the public shareholding may fall below the mandatory 25% threshold, requiring Rekvina Laboratories to take measures for future regulatory compliance. The open offer provides a mechanism for existing public shareholders to exit.
Risks to watch
The primary risks for investors include the company's persistent financial losses and its negative net worth, indicating poor balance sheet health. Additionally, the potential non-compliance with minimum public shareholding norms post-transaction necessitates future regulatory actions.
Peer comparison
(No specific peer comparison data was available in the filing.)
Context metrics (time-bound)
- Open Offer Size: 28,90,100 shares (26% of Expanded Share Capital)
- Offer Price: ₹10 per share
- Maximum Consideration: ₹2.89 crore
- Offer Period: July 1, 2026 – July 14, 2026
- FY 2026 Revenue: ₹1.27 crore
- FY 2026 Net Loss: ₹0.25 crore
- FY 2025 Net Loss: ₹0.14 crore
- Net Worth (as of March 31, 2026): (₹1.23 crore)
What to track next
Investors should closely monitor the response to the open offer and any subsequent management plans to address the company's financial performance and balance sheet health. Compliance with minimum public shareholding regulations will also be a key point to track.